AEON
AEON
Positions held
Your positionsAEON isn't in your positions.
Add it to see shares, cost, and P&L here.
Fundamentals
| Market cap | — | Enterprise value | — | Trailing P/E | — | Forward P/E | — |
| PEG | — | Price / book | — | Beta | — | Dividend yield | — |
| Revenue growth | — | Earnings growth | — | Gross margin | — | Operating margin | — |
| Profit margin | — | ROE | — | ROA | — | Debt / equity | — |
| Current ratio | — | Free cash flow | — | Analyst recommendation | — | Mean target | — |
| 52w high | — | 52w low | — |
Quarterly
No data yet.
Yearly (6y)
No data yet.
No flags
• No distress or material-risk keywords in recent headlines (keyword scan only — not a guarantee).
News
2026-10-05 · AEON: Initiating Coverage – Imitation is a Sincere Form of Flattery: Seeking a Botox Biosimilar
2026-09-30 · AEON Biopharma FDA Type 2b Meeting Feedback Clarifies Biosimilar Development Plan for ABP-450
2026-09-10 · Top Premarket Gainers
2026-09-09 · AEON Announces Positive Pilot Forced Degradation Results Supporting Analytical Comparability of ABP-450 to BOTOX®
2026-08-24 · AEON Biopharma Designates Former FDA Neuroscience Leader Paul Lee, M.D., Ph.D. as Acting Chief Regulatory Officer
2026-08-19 · AEON Reports Expanded Structural Data Supporting Molecular Similarity of ABP-450 to BOTOX®
2026-08-12 · AEON Biopharma Reports Second Quarter 2026 Financial Results and Provides Corporate Update
2026-08-03 · AEON Biopharma Regains Compliance with NYSE American Continued Listing Standards
2026-07-30 · Humana upgraded, Las Vegas Sands downgraded: Wall Street's top analyst calls
2026-07-14 · Aeon Biopharma Prices $13.8 Million Underwritten Public Offering
Price (daily)
Full chart · RSI · MACD · patterns